CA2345767A1 - Therapy for improving cognition - Google Patents
Therapy for improving cognition Download PDFInfo
- Publication number
- CA2345767A1 CA2345767A1 CA002345767A CA2345767A CA2345767A1 CA 2345767 A1 CA2345767 A1 CA 2345767A1 CA 002345767 A CA002345767 A CA 002345767A CA 2345767 A CA2345767 A CA 2345767A CA 2345767 A1 CA2345767 A1 CA 2345767A1
- Authority
- CA
- Canada
- Prior art keywords
- atypical antipsychotic
- patients suffering
- acetylcholinesterase inhibitor
- alzheimer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98203454 | 1998-10-16 | ||
EP98203454.8 | 1998-10-16 | ||
PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2345767A1 true CA2345767A1 (en) | 2000-04-27 |
Family
ID=8234219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002345767A Abandoned CA2345767A1 (en) | 1998-10-16 | 1999-10-12 | Therapy for improving cognition |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1121131A2 (xx) |
JP (1) | JP2002527469A (xx) |
KR (1) | KR20010072878A (xx) |
CN (1) | CN1367697A (xx) |
AU (1) | AU6472799A (xx) |
BG (1) | BG105302A (xx) |
BR (1) | BR9914419A (xx) |
CA (1) | CA2345767A1 (xx) |
EE (1) | EE200100136A (xx) |
HK (1) | HK1039745A1 (xx) |
HR (1) | HRP20010262A2 (xx) |
HU (1) | HUP0103781A3 (xx) |
ID (1) | ID28441A (xx) |
IL (1) | IL142588A0 (xx) |
NO (1) | NO20011403D0 (xx) |
PL (1) | PL348107A1 (xx) |
SK (1) | SK4592001A3 (xx) |
TR (1) | TR200101082T2 (xx) |
WO (1) | WO2000023057A2 (xx) |
ZA (1) | ZA200103081B (xx) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
JP5067998B2 (ja) | 2001-10-30 | 2012-11-07 | ノバルティス アーゲー | イロペリドンおよび星形ポリマーのデポー製剤 |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
US20050232990A1 (en) * | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
AU2004325725A1 (en) * | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤 |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
US10925834B2 (en) | 2015-05-22 | 2021-02-23 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE183084T1 (de) * | 1991-05-14 | 1999-08-15 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
DK1011678T3 (da) * | 1997-08-11 | 2008-05-05 | Univ South Florida | Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser |
EP2338482A3 (en) * | 1998-04-14 | 2011-12-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
-
1999
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Application Discontinuation
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403D0/no not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU6472799A (en) | 2000-05-08 |
NO20011403L (no) | 2001-03-20 |
SK4592001A3 (en) | 2001-12-03 |
HK1039745A1 (zh) | 2002-05-10 |
EE200100136A (et) | 2002-06-17 |
NO20011403D0 (no) | 2001-03-20 |
WO2000023057A3 (en) | 2000-07-27 |
HRP20010262A2 (en) | 2002-06-30 |
ZA200103081B (en) | 2002-07-12 |
WO2000023057A2 (en) | 2000-04-27 |
HUP0103781A2 (hu) | 2002-03-28 |
TR200101082T2 (tr) | 2001-09-21 |
BR9914419A (pt) | 2001-06-26 |
ID28441A (id) | 2001-05-24 |
BG105302A (en) | 2001-11-30 |
HUP0103781A3 (en) | 2003-09-29 |
PL348107A1 (en) | 2002-05-06 |
EP1121131A2 (en) | 2001-08-08 |
IL142588A0 (en) | 2002-03-10 |
JP2002527469A (ja) | 2002-08-27 |
KR20010072878A (ko) | 2001-07-31 |
CN1367697A (zh) | 2002-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2345767A1 (en) | Therapy for improving cognition | |
RU93004484A (ru) | Производные пиразола, способ их получения и содержащие их фармацевтические композиции | |
YU66600A (sh) | Farmaceutski preparati koji mogu da budu gelirani | |
IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
US6291471B1 (en) | Use of apomorphine for the treatment of organic erectile dysfunction in males | |
MD1699F2 (ro) | Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei | |
CA2433585A1 (en) | Pharmaceutical compositions containing donepezil hydrochloride | |
ATE224712T1 (de) | Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
JP2019510039A5 (xx) | ||
CA2378613A1 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
JPH08245417A (ja) | 鼻内投与のための薬学的非無機塩類液剤 | |
CN1317030C (zh) | 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病 | |
HUT61743A (en) | Process for producing 2-(piperidin-1-yl)-ethanol derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
KR20060130619A (ko) | 유기 화합물의 조합물 | |
HUP0102987A3 (en) | Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
JP4135263B2 (ja) | クリーム状洗浄剤組成物 | |
CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque | |
JPH0678227B2 (ja) | 4−エチル−2−ヒドロキシイミノ−5−ニトロ−3−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤 | |
EP0671908B1 (en) | Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers | |
DE602006016168D1 (de) | 1,3,5-triazepin-dionen zur Behandlung von Malaria | |
WO2001093832A3 (en) | Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery | |
RU2001113270A (ru) | Лечение, направленное на улучшение познавательной способности | |
HU9904440D0 (en) | Pharmaceutical composition for the prevention and the treatment of fungus-infected and process producing the agents | |
HUT70439A (en) | Injectable solution for administration of one or more active compounds in situ and process for its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |